Biodesix (BDSX) Q4 2025: Lung Diagnostics Revenue Jumps 46% as Primary Care Channel Expands

February 26, 2026 | By EarningsIQ Research

Biodesix capped 2025 with accelerated revenue growth and a pivotal expansion in its primary care channel, fueling a 46% surge in lung diagnostics revenue. Gross margin leadership and operational leverage signal a maturing business model, while management eyes deeper primary care penetration and disciplined pipeline advancement for 2026. Investors should monitor the sustainability of sales productivity and the pace of reimbursement-driven ASP gains as Biodesix targets another year of double-digit growth.

Summary

• Primary Care Channel Drives Growth: Expanded sales focus pushed primary care to 12% of lung test volumes, up sharply YoY.
• Margin and Cash Milestones Achieved: Gross margins reached 83% and adjusted EBITDA turned positive, marking a key inflection.
• 2026 Strategy Centers on Sales Leverage: Management targets further sales force scaling and disciplined pipeline progress.

Business Overview

Biodesix is a diagnostics company focused on personalized medicine, leveraging genomics, proteomics, and radiomics combined with AI to deliver diagnostic tests primarily in lung disease. The company generates revenue through two main segments: lung diagnostics, which includes proprietary tests for lung nodule management, and development services, which provides multi-omic and R&D expertise to biopharma and diagnostic partners. Lung diagnostics is the dominant revenue driver, while development services offers diversification and partnership opportunities.

Performance Analysis

Biodesix delivered a breakout fourth quarter, with total revenue up 41% and lung diagnostics revenue climbing 46% year-over-year. This growth was fueled by both higher test volumes—up 23% to 18,000 tests—and a notable increase in average revenue per test, driven by improved payer coverage and revenue cycle management. Primary care accounted for 12% of notified lung test volumes, up from 11% in Q3, reflecting success in expanding beyond specialist channels.

Gross margin improvement was a central theme, with Q4 margins reaching 83%, a 400 basis point increase, supported by workflow optimization and scale. Operating expenses rose 14%, aligned with a ramp in sales and marketing to support growth, yet operating leverage was evident as adjusted EBITDA turned positive for the first time. Development services grew 12% in the quarter, underpinned by new partnerships with Thermo Fisher and Bio-Rad, and the company exited the year with $11.8 million in contracted business for 2026.

• Sales Force Expansion: The field team grew to 97 reps, enabling both deeper market penetration and higher test volumes.
• ASP and Reimbursement: Average revenue per test increased due to payer coverage gains and improved collections, including $1 million from older claims.
• Cash Position Strengthened: Pro forma cash reached $33.7 million after at-the-market proceeds and term loan extension, reducing near-term liquidity risk.

Biodesix’s performance reflects a business transitioning from early-stage growth to operational maturity, with margin expansion and cash discipline supporting its forward trajectory. The company’s ability to maintain sales productivity and further penetrate primary care will be critical in sustaining this momentum.

Executive Commentary

Strategic Positioning

1. Primary Care Penetration and Channel Expansion

Biodesix’s three-tier commercial strategy has progressively expanded from interventional pulmonologists to general pulmonology and now to primary care, which manages roughly half of the lung nodule market. This expansion is unlocking new volume, as evidenced by primary care’s share of notified test volumes rising to 12%. Management plans to add approximately six sales reps per quarter in 2026 to further drive penetration and capitalize on under-addressed referral networks.

2. Margin Leadership and Operational Leverage

Gross margin expansion to 83% positions Biodesix at the upper end of the diagnostics sector, reflecting both improved reimbursement and workflow efficiencies. The company’s first quarter of positive adjusted EBITDA demonstrates that its model can scale profitably, with operating leverage expected to increase as the sales force matures and productivity rises.

3. Disciplined Pipeline and Partner Strategy

Biodesix is advancing a multi-omic pipeline, including novel MRD (minimal residual disease) tests and expanded Varistrat applications, but is taking a disciplined approach to commercialization. Management emphasized that no new launches are planned in the next 12 months, prioritizing reimbursement readiness and clinical validation. Partnerships with Thermo Fisher and Bio-Rad validate Biodesix’s R&D capabilities and provide non-dilutive growth avenues.

4. Real-World Evidence and Data-Driven Adoption

Clinical data and real-world evidence remain central to adoption, with multiple presentations and publications supporting notified test utility. The company continues to encourage independent clinician-led studies, aiming to build payer and provider confidence and drive guideline inclusion over time.

5. Cash Management and Capital Flexibility

Strengthened liquidity through at-the-market proceeds and loan extension reduces near-term financing risk and provides flexibility to invest in commercial expansion. Management signaled comfort with the current cash position, with no immediate plans for further capital raises absent unforeseen circumstances.

Key Considerations

The quarter marks a strategic inflection for Biodesix, but the path forward will test the durability of its commercial and operational gains. Key considerations for investors include:

• Primary Care Scaling Trajectory: Sustained double-digit growth from primary care will be essential to maintain volume momentum as specialist channels mature.
• ASP and Reimbursement Sustainability: Recent gains in average revenue per test are tied to payer coverage improvements; ongoing payer adoption and claims collection efficiency will determine ASP stability.
• Sales Force Productivity Ramping: The ability of newly hired reps to reach full productivity, and the speed of their ramp, will shape near-term revenue growth and operating leverage.
• Pipeline Commercialization Discipline: Management’s cautious approach limits near-term pipeline risk but could delay incremental revenue from new products if reimbursement timelines slip.
• Development Services Diversification: Growth in this segment provides revenue diversity, but its scale relative to core lung diagnostics remains modest.

Risks

Biodesix faces several execution and market risks. The most immediate are the potential for slower-than-expected ramp in primary care rep productivity and the risk that payer dynamics or claims collections could pressure ASPs. Seasonality and weather disruptions, as noted in Q1 guidance, may create short-term revenue volatility. Longer-term, delays in pipeline reimbursement or guideline inclusion could limit the pace of expansion into new indications, while competitive dynamics in lung diagnostics remain a persistent threat to share and pricing power.

Forward Outlook

For Q1 2026, Biodesix guided to:

• Seasonal step-down in average selling price (ASP) and test volumes, consistent with prior years and impacted by weather disruptions.

For full-year 2026, management raised guidance to:

• $106 to $112 million in annual revenue, implying 23% growth at the midpoint.
• Continued improvement toward sustained adjusted EBITDA positivity.

Management highlighted several factors that will drive results:

• Increased productivity and tenure of the expanded sales force, especially in primary care.
• Further ASP stabilization from payer coverage and claims collection improvements.
• Ongoing development services growth and operational leverage.

Takeaways

Biodesix’s Q4 performance underscores a business transitioning from growth to operational leverage, with a scalable sales model and margin leadership. The company’s deliberate approach to pipeline advancement and cash management reduces near-term risk, while channel expansion offers a clear path to continued growth.

• Primary Care Expansion Is the Growth Engine: The shift into primary care channels is unlocking new volume and diversifying referral sources, a trend that should compound as rep productivity increases.
• Margin and Cash Strength Support Strategic Flexibility: Gross margin leadership and improved liquidity position Biodesix to invest in commercial scaling and weather near-term volatility.
• Watch for Rep Ramp and ASP Trends: Investors should monitor the ramp speed of new sales hires and the durability of ASP gains as forward indicators of top-line and profitability progress.

Conclusion

Biodesix exits 2025 with accelerating revenue, expanding margins, and a maturing commercial engine. The company’s success in primary care and disciplined capital allocation provide a solid foundation for 2026, though execution around sales productivity and reimbursement will be critical to sustaining momentum.

Industry Read-Through

Biodesix’s results highlight the growing importance of primary care channels in diagnostics market expansion, suggesting that companies able to bridge specialist and generalist referral networks can unlock incremental growth. The focus on margin optimization and operational leverage signals a broader industry move toward profitability over pure volume growth, especially as payers scrutinize reimbursement. Partnerships with major life science players indicate that multi-omic and AI-driven diagnostics are increasingly valued by both providers and industry collaborators. Competitors should note the rising bar for gross margin performance and the strategic value of payer engagement in driving both ASP and adoption.

BDSX Healthcare Diagnostics Primary care Lung cancer Reimbursement Margin expansion Sales productivity